Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mabtrx Biosciences is a biotechnology company focused on the discovery and development of novel antibody-based therapeutics. Established in late 2025 as a joint venture between ArrowMark Partners and Viking Global Investors, the company operates as a wholly owned subsidiary of AMVKG LS. Mabtrx utilizes OmniAb's proprietary transgenic animal platforms, including the OmnidAb single-domain technology, to identify and optimize fully human antibodies against high-value drug targets. The company aims to advance a pipeline of next-generation biologics across various therapeutic areas through an incubated development model that leverages strategic discovery partnerships.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mabtrx Biosciences.